Humana’s (HUM) “Buy” Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Humana (NYSE:HUM) in a research report released on Wednesday morning. The firm currently has a $285.00 target price on the insurance provider’s stock.

A number of other equities research analysts have also weighed in on the stock. BMO Capital Markets upped their target price on shares of Humana from $290.00 to $300.00 and gave the stock an outperform rating in a report on Friday, November 10th. ValuEngine upgraded shares of Humana from a hold rating to a buy rating in a report on Friday, September 1st. Royal Bank of Canada restated a sector perform rating and issued a $242.00 target price (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Credit Suisse Group lowered their target price on shares of Humana from $256.00 to $246.00 and set a neutral rating on the stock in a report on Friday, November 10th. Finally, Zacks Investment Research lowered shares of Humana from a strong-buy rating to a hold rating in a report on Tuesday, October 17th. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $256.30.

Shares of Humana (HUM) traded up $1.60 during midday trading on Wednesday, hitting $256.24. 1,004,000 shares of the stock traded hands, compared to its average volume of 1,375,566. Humana has a 52-week low of $186.25 and a 52-week high of $264.56. The firm has a market capitalization of $36,377.89, a price-to-earnings ratio of 21.73, a P/E/G ratio of 1.75 and a beta of 0.88. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the prior year, the business earned $3.18 earnings per share. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. sell-side analysts forecast that Humana will post 11.63 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.59%.

A number of hedge funds have recently modified their holdings of HUM. WFG Advisors LP grew its position in shares of Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the period. Fieldpoint Private Securities LLC bought a new position in shares of Humana during the 3rd quarter valued at approximately $115,000. Acrospire Investment Management LLC bought a new position in shares of Humana during the 2nd quarter valued at approximately $120,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Humana by 139.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after acquiring an additional 325 shares during the period. Finally, Fiduciary Trust Co. bought a new position in shares of Humana during the 2nd quarter valued at approximately $135,000. 94.19% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Humana’s (HUM) “Buy” Rating Reaffirmed at Cowen” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2017/12/14/humanas-hum-buy-rating-reaffirmed-at-cowen.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Humana’s (HUM) “Buy” Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Humana (NYSE:HUM) in a research report released on Wednesday morning. The firm currently has a $285.00 target price on the insurance provider’s stock.

A number of other equities research analysts have also weighed in on the stock. BMO Capital Markets upped their target price on shares of Humana from $290.00 to $300.00 and gave the stock an outperform rating in a report on Friday, November 10th. ValuEngine upgraded shares of Humana from a hold rating to a buy rating in a report on Friday, September 1st. Royal Bank of Canada restated a sector perform rating and issued a $242.00 target price (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Credit Suisse Group lowered their target price on shares of Humana from $256.00 to $246.00 and set a neutral rating on the stock in a report on Friday, November 10th. Finally, Zacks Investment Research lowered shares of Humana from a strong-buy rating to a hold rating in a report on Tuesday, October 17th. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of $256.30.

Shares of Humana (HUM) traded up $1.60 during midday trading on Wednesday, hitting $256.24. 1,004,000 shares of the stock traded hands, compared to its average volume of 1,375,566. Humana has a 52-week low of $186.25 and a 52-week high of $264.56. The firm has a market capitalization of $36,377.89, a price-to-earnings ratio of 21.73, a P/E/G ratio of 1.75 and a beta of 0.88. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the prior year, the business earned $3.18 earnings per share. The business’s quarterly revenue was down 3.0% compared to the same quarter last year. sell-side analysts forecast that Humana will post 11.63 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.62%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.59%.

A number of hedge funds have recently modified their holdings of HUM. WFG Advisors LP grew its position in shares of Humana by 4.5% during the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the period. Fieldpoint Private Securities LLC bought a new position in shares of Humana during the 3rd quarter valued at approximately $115,000. Acrospire Investment Management LLC bought a new position in shares of Humana during the 2nd quarter valued at approximately $120,000. Northwestern Mutual Wealth Management Co. grew its position in shares of Humana by 139.5% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after acquiring an additional 325 shares during the period. Finally, Fiduciary Trust Co. bought a new position in shares of Humana during the 2nd quarter valued at approximately $135,000. 94.19% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Humana’s (HUM) “Buy” Rating Reaffirmed at Cowen” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2017/12/14/humanas-hum-buy-rating-reaffirmed-at-cowen.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply